

EARLEY TERMINATIONS GRANTED—Continued

[June 1, 2012 Thru June 30, 2012]

06/29/2012

20120974	G	Verizon Communications Inc.; Apollo Investment Fund V, L.P.; Verizon Communications Inc.
20121000	G	The Resolute Fund 11 Maritime Partnership, L.P.; Bollinger Shipyards, Inc.; The Resolute Fund II Maritime Partnership, L.P.
20121006	G	Brentwood Associates Private Equity IV, L.P.; ACI Capital America Fund, L.P.; Brentwood Associates Private Equity IV, L.P.
20121008	G	Permira IV Continuing L.P.2; Intelligrated, Inc.; Permira IV Continuing L.P.2.
20121014	G	Holly Energy Partners, L.P.; HollyFrontier Corporation; Holly Energy Partners, L.P.
20121015	G	Francisco Partners III, L.P.; Cross Match Technologies, Inc.; Francisco Partners III, L.P.
20121018	G	Wesco International, Inc.; Caxton-Iseman (Conney), L.P.; Wesco International, Inc.
20121019	G	salesforce.com, inc.; Buddy Media, Inc.; salesforce.com, inc.
20121020	G	ORG Chemical Holdings, LLC; McFerrin Dynasty Trust; ORG Chemical Holdings, LLC.
20121023	G	EQT VI (No.1) Limited Partnership; BSN medical Luxembourg Holding S.a.r.l.; EQT VI (No. 1) Limited Partnership.
20121025	G	WPP plc; General Atlantic Partners 83, LP; WPP plc.
20121031	G	Paul G. Desmarais; IntegraMed America, Inc.; Paul G. Desmarais.
20121034	G	Calumet Specialty Products Partners, L.P.; Royal Purple, Inc.; Calumet Specialty Products Partners, L.P.
20121037	G	J.H. Whitney VII, L.P.; Beecken Petty O'Keefe QP Fund II, L.P.; J.H. Whitney VII, L.P.

FOR FURTHER INFORMATION CONTACT:
Renee Chapman, Contact Representative
or

Theresa Kingsberry, Legal Assistant.
Federal Trade Commission, Premerger
Notification Office, Bureau of
Competition, Room H-303,
Washington, DC 20580, (202) 326-
3100.

By direction of the Commission.

Richard C. Donohue,

[FR Doc. 2012-17464 Filed 7-19-12; 8:45 am]

BILLING CODE 6750-01-M

FEDERAL TRADE COMMISSION

[File No. 121 0144]

Novartis AG; Analysis of Agreement Containing Consent Orders to Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed consent agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the draft complaint and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before August 16, 2012.

ADDRESSES: Interested parties may file a comment online or on paper, by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Write “Novartis Fougara, File No. 121 0144” on your comment, and

file your comment online at <http://www.ftc.gov/ftc/1210144>, by following the instructions on the Web-based form. If you prefer to file your comment on paper, mail or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Room H-113 (Annex D), 600 Pennsylvania Avenue NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT:
Christine Tasso (202-326-2232), FTC,
Bureau of Competition, 600
Pennsylvania Avenue NW., Washington,
DC 20580.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46(f), and 2.34 the Commission Rules of Practice, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for July 16, 2012), on the World Wide Web, at <http://www.ftc.gov/ftc/1210144>. A paper copy can be obtained from the FTC Public Reference Room, Room 130-H, 600 Pennsylvania Avenue NW., Washington, DC 20580, either in person or by calling (202) 326-2222.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before August 16, 2012. Write “Novartis Fougara, File No. 121 0144” on your comment. Your comment B including

your name and your state B will be placed on the public record of this proceeding, including, to the extent practicable, on the public Commission Web site, at <http://www.ftc.gov/ftc/1210144>. As a matter of discretion, the Commission tries to remove individuals' home contact information from comments before placing them on the Commission Web site.

Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, like anyone's Social Security number, date of birth, driver's license number or other state identification number or foreign country equivalent, passport number, financial account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, like medical records or other individually identifiable health information. In addition, do not include any “[t]rade secret or any commercial or financial information which is obtained from any person and which is privileged or confidential,” as provided in Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

If you want the Commission to give your comment confidential treatment, you must file it in paper form, with a request for confidential treatment, and you have to follow the procedure explained in FTC Rule 4.9(c), 16 CFR

supply that participate in the market. Market participants consistently characterize generic drug markets as commodity markets in which the number of generic suppliers has a direct impact on pricing. Customers and competitors alike have confirmed that the price of a generic pharmaceutical product decreases with the entry of the second, third, and even fourth and fifth generic competitor. Further, customers generally believe that having at least four suppliers in a generic pharmaceutical market produces the most competitive prices.

Evidence gathered during our investigation indicates that anticompetitive effects are likely to result from a decrease in the number of independent competitors in the markets at issue. The Proposed Acquisition, by reducing an already limited number of competitors or potential competitors in each of these markets, would cause anticompetitive harm to U.S. consumers by increasing the likelihood of higher post-acquisition prices. In the market for generic calcipotriene topical solution, Novartis and Fougera are two of only three suppliers. In the lidocaine-prilocaine cream 30 gram tube market, Novartis and Fougera are two of only three suppliers of the product, and the Proposed Acquisition would eliminate Fougera as an independent competitor to Novartis leaving only Hi-Tech. In the